Full Press Release Details
PHARMA, INC., PRICES $8,000,000 COMMON STOCK OFFERING
GA and BOTHELL, WA. May 1, 2018 - COCRYSTAL PHARMA, INC. (NASDAQ: COCP), ("Cocrystal" or the "Company")
a clinical stage biotechnology company focused on developing innovative antiviral therapeutics, today announced the pricing
of an underwritten public offering of 4,210,527 shares of its common stock at a price to the public of $1.90 per share. The gross
proceeds to Cocrystal from this offering are expected to be approximately $8,000,000 before deducting underwriting discounts and
commissions and other estimated offering expenses. Cocrystal has granted the underwriters a 45-day option to purchase up to an
additional 631,578 shares of common stock to cover over-allotments, if any. The offering is expected to close on May 3, 2018 subject
to customary closing conditions.
Global Partners, offering securities through Euro Pacific Capital, Inc., is acting as sole book-running manager for the offering.
registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission (the "SEC")
and became effective on October 10, 2017.
offering is being made pursuant to an effective shelf registration statement on Form S-3 (No. 333-220632) previously filed with
the SEC. A preliminary prospectus supplement and accompanying prospectus describing the terms of the proposed offering have been
filed with the SEC and are available on the SEC's website located at http://www.sec.gov. Electronic copies of the preliminary
prospectus supplement may be obtained from A.G.P./Alliance Global Partners, offering securities through Euro Pacific Capital,
Inc., 590 Madison Avenue, 36th Floor, New York, NY 10022 or via telephone at 212-624-2060 or email: prospectus@allianceg.com.
Before investing in this offering, interested parties should read in their entirety the prospectus supplement and the accompanying
prospectus and the other documents that Cocrystal has filed with the SEC that are incorporated by reference in such prospectus
supplement and the accompanying prospectus, which provide more information about Cocrystal and such offering.
press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these
securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such state or jurisdiction.
Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target
the replication machinery of hepatitis viruses, influenza viruses, and noroviruses.
statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995.
These statements may be identified by the use of forward-looking words such as "anticipate," "believe,"
"forecast," "estimated" and "intend," among others. These forward-looking statements are based
on Cocrystal's current expectations and actual results could differ materially. There are a number of factors that could
cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are
not limited to, risks arising from: whether or not Cocrystal will be able to raise capital through this offering or consummate
this offering, the final terms of the offering, the satisfaction of customary closing conditions, prevailing market conditions,
the impact of general economic industry or political conditions in the United States or globally, and other factors described
in the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K
filed with the Securities and Exchange Commission. The Company has based these forward-looking statements on its current expectations
and assumptions about future events. While management considers these expectations and assumptions to be reasonable, they are
inherently subject to significant business, economic, competitive, regulatory, and other risks, contingencies, and uncertainties,
most of which are difficult to predict and many of which are beyond the Company's control. The Company does not assume any
obligations to update any of these forward-looking statements.
Thomas Communications, LLC